teaser
Galen has unveiled the new Trustsaver Collection consisting of three established products that offer proven efficacy, tolerability and compliance, along with significant savings over the current market leading brands (excluding all oxybutynin preparations), reaffirming Galen’s ongoing commitment to remain competitive on price.
The three brands that currently make up the Trustsaver Collection are: Flotros 20mg tablets: for the symptomatic treatment of urge incontinence/overactive bladder, Laxido Orange: for the treatment of chronic constipation, and Calceos Chewable Tablets: a calcium and vitamin D3 supplement.
The switch to Laxido Orange alone offers a 20% saving against the current market leading macrogol 3350 + electrolyte brand, translating to £6.2M in potential savings per year to the NHS. By also adding Flotros and Calceos, the potential savings on offer grow to £45M. This comes in addition to the recent extension, until at least 2013, of Galen’s price pledge on Calceos, promising to remain less expensive than the two current market leading calcium/vitamin D3 supplements available in the UK. Galen has already gone beyond this pledge twice, with price reductions in 2008 and 2010.
PCTs are under considerable pressure to make savings in order to meet financial targets. For medicines management teams, one option is to adopt products that offer cost savings without compromising patient care. A hypothetical case study, based on a real-life example of a PCT, demonstrates that an average-sized PCT with a population of around 325,000 people could save up to £258,500 in one year by completely switching to the brands in the Trustsaver Collection. This may represent a significant portion of the savings required from the drugs budget.
Mark Scrutton, Managing Director of Galen, commented: “The launch of the Trustsaver Collection is an important milestone in Galen’s ongoing commitment to provide cost-effective treatment options to healthcare professionals without compromising patient care. At Galen, we are committed to helping PCTs meet their strategic challenges, and in particular achieve savings both through the product offering and developing bespoke services and initiatives.”
